Doublet vs Single-Agent Maintenance Therapy in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis

References

• SiegelR, MaJ, ZouZ, JemalA. Cancer statistics, 2014 CA Cancer J Clin. 2014;64(1):9–29.24399786
   PubMed Web of Science ®Google Scholar
• ShepherdFA, BunnPA, Paz-AresL. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013:339–346.
   Google Scholar
• BlakelyC, JahanT. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(10):1607–1618.21999134
   PubMed Web of Science ®Google Scholar
• MinamiS, KijimaT. Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2015;6:13–25.28210147
   PubMedGoogle Scholar
• LeeJE, ChungCU. Update on the evidence regarding maintenance therapy. Tuberc Respir Dis. 2014;76(1):1–7.
   PubMedGoogle Scholar
• GerberDE, SchillerJH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013;31(8):1009–1020.23401441
   PubMed Web of Science ®Google Scholar
• WangQ, HuangH, ZengX, MaY, ZhaoX, HuangM. Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials. Peer J. 2016;4:e2550.27781159
   PubMed Web of Science ®Google Scholar
• HuX, PuK, FengX, et al. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(3):e0149247.26954503
   PubMed Web of Science ®Google Scholar
• LuS, YuY, ChenZ, YeX, LiZ, NiuX. Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. Lung. 2015;193(5):805–814.26119960
   PubMed Web of Science ®Google Scholar
• NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE); 2006 Available from: http://ctep.cancer.gov/reporting/
   Google Scholar
• ZintzarasE, IoannidisJP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–137.15593093
   PubMed Web of Science ®Google Scholar
• YusufS, PetoR, LewisJ, CollinsR, SleightP. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371.2858114
   PubMed Web of Science ®Google Scholar
• BeggCB, MazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.7786990
   PubMed Web of Science ®Google Scholar
• MoherD, PhamB, JonesA, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–613.9746022
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.19621072
   PubMed Web of Science ®Google Scholar
• BarlesiF, ScherpereelA, GorbunovaV, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044–1052.24585722
   PubMed Web of Science ®Google Scholar
• BarlesiF, ScherpereelA, RittmeyerA, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004–3011.23835708
   PubMed Web of Science ®Google Scholar
• NihoS, OheY, OhmatsuH, et al. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study. Lung Cancer. 2017;108:66–71.28625650
   PubMed Web of Science ®Google Scholar
• CiuleanuTE, AhmedS, KimJH, et al. Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Br J Cancer. 2017;117(6):757–766.28772281
   PubMed Web of Science ®Google Scholar
• KarayamaM, InuiN, FujisawaT, et al. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. Eur J Cancer. 2016;58:30–37.26922170
   PubMed Web of Science ®Google Scholar
• PatelJD, SocinskiMA, GaronEB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349–4357.24145346
   PubMed Web of Science ®Google Scholar
• JohnsonBE, KabbinavarF, FehrenbacherL, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(31):3926–3934.24101054
   PubMed Web of Science ®Google Scholar
• SullivanI, PlanchardD. Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer. Future Oncol. 2016;12(7):945–961.26892300
   PubMed Web of Science ®Google Scholar
• GenestretiG, di Battista M, Cavallo G, Bartolotti M, Brandes AA. Maintenance therapy in non-small cell lung cancer. Expert Rev Anticancer Ther. 2015;15(7):839–846.26027675
   PubMed Web of Science ®Google Scholar
• GentzlerRD, PatelJD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2014;6(1):4–15.24381656
   PubMed Web of Science ®Google Scholar
• ZhangL, MaS, SongX, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012;13(5):466–475.22512843
   PubMed Web of Science ®Google Scholar
• PérolM, ChouaidC, PérolD, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(28):3516–3524.22949150
   PubMed Web of Science ®Google Scholar
• Paz-AresL, de MarinisF, DediuM, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255.22341744
   PubMed Web of Science ®Google Scholar
• CappuzzoF, CiuleanuT, StelmakhL, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521–529.20493771
   PubMed Web of Science ®Google Scholar
• CiuleanuT, BrodowiczT, ZielinskiC, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–1440.19767093
   PubMed Web of Science ®Google Scholar
• Paz-AresLG, de MarinisF, DediuM, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–2902.23835707
   PubMed Web of Science ®Google Scholar